PDF herunterladen
Aktuelle Dermatologie 2002; 28(8/9): 290-296
DOI: 10.1055/s-2002-33963
Tumormarker
© Georg Thieme Verlag Stuttgart · New York

Verlaufsbeobachtung des fernmetastasierten Melanoms mit der Laktatdehydrogenase und dem C-reaktiven Protein

Study of the Course of Melanoma with Distant Metastases Using Lactate Dehydrogenase and C-Reactive ProteinM.  Deichmann1
  • 1Universitäts-Hautklinik Heidelberg (Direktor: Prof. Dr. D. Petzoldt)
Weitere Informationen

Publikationsverlauf

Publikationsdatum:
10. September 2002 (online)

Auch verfügbar auf
   Lizenzen und Reprints

Zusammenfassung

Zur Evaluierung von serologischen Verlaufsparametern der fernmetastasierten Melanom-Erkrankung wurden drei prospektive Studien durchgeführt. Die Ergebnisse der Staging-Untersuchungen wurden als unabhängiger Referenz-Standard zur Diagnose einer Erkrankungs-Progredienz verwandt, und Interleukin-6 (Il-6), sein Surrogat C-reaktives Protein (CRP) und der konventionelle Parameter Laktatdehydrogenase (LDH) wurden zum Zeitpunkt der Staging-Untersuchungen im Serum bestimmt. Zum Vergleich wurden die Melanom-Marker S100β und „melanoma inhibitory activity” (MIA) in den Seren gemessen. Die Patienten mit Progredienz der Metastasierung wiesen statistisch signifikant höhere Konzentrationen der Serumparameter als die Patienten mit Therapieansprechen auf, wenn beide Gruppen durch Medianwerte verglichen wurden. Mit der Fläche unter den „Receiver Operating Characteristic” (ROC)-Kurven zeigten sich sowohl Il-6, sein Surrogat CRP und die LDH als auch S100β und MIA geeignet, eine Progression der Metastasierung tendenziell zu erkennen. In der multiplen logistischen Regressions-Analyse resultierte die LDH als relevanter Faktor. Aufgrund ihrer hohen Korrelationen mit der LDH konnten S100β und MIA die Information der LDH nur geringfügig verbessern. Unter Anwendung von „classification and regression trees” (CART) erwies sich das CRP mit einem Grenzwert von 0,5 mg/dl als der am meisten relevante Parameter.

Abstract

Monitoring melanoma patients suffering from distant metastases (American Joint Committee on Cancer stage IV), we evaluated serum markers for the ability to discriminate progressive from non-progressive disease. In three prospective studies, results of staging examinations were used as independent reference standard for diagnosing progressive disease, and interleukin-6 (Il-6), its surrogate C-reactive protein (CRP) and the conventional parameter lactate dehydrogenase (LDH) were determined in serum just before. For comparison, the melanoma markers S100β and melanoma inhibitory activity (MIA) were measured in the sera. We found all tested serum parameters to be significantly elevated in progressive disease by median values. Calculating the areas under the Receiver Operating Characteristic (ROC) curves, Il-6, its surrogate CRP and LDH as well as S100β and MIA were useful in diagnosing progressive disease. By multiple logistic regression analysis, LDH resulted as relevant factor. S100β and MIA did not provide additional significant information as they highly correlated with LDH with respect to clinical outcome. Applying classification and regression trees (CART), we found CRP with a cut off value of 0.5 mg/dl to be the most relevant serum marker.

Literatur

  • 1 Mouawad R, Benhammouda A, Rixe O, Antoine E C, Borel C, Weil M, Khayat D, Soubrane C. Endogenous interleukin 6 levels in patients with metastatic malignant melanoma, correlation with tumor burden.  Clin Cancer Res. 1996;  2 1405-1409
    PubMedGoogle Scholar
  • 2 Tartour E, Dorval T, Mosseri V, Deneux L, Mathiot C, Brailly H, Montero F, Joyeux I, Pouillart P, Fridman W H. Serum interleukin 6 and C-reactive protein levels correlate with resistance to Il-2 therapy and poor survival in melanoma patients.  Br J Cancer. 1994;  69 911-913
    PubMedGoogle Scholar
  • 3 Tartour E, Blay J Y, Dorval T, Escudier B, Mosseri V, Douillard J Y, Deneux L, Gorin I, Negrier S, Mathiot C, Pouillart P, Fridman W H. Predictors of clinical response to interleukin-2-based immunotherapy in melanoma patients, a French multiinstitutional study.  J Clin Oncol. 1996;  14 1697-1703
    PubMedGoogle Scholar
  • 4 Candi E, Knight R A, Spinedi A, Guerrieri P, Melino G. A possible growth factor role of Il-6 in neuroectodermal tumors.  J Neurooncol. 1997;  31 115-122
    CrossrefPubMedGoogle Scholar
  • 5 Kishimoto T, Akira S. Interleukin-6 and its receptor, a paradigm for cytokines.  Science. 1992;  258 593-597
    PubMedGoogle Scholar
  • 6 Lee J D, Sievers T M, Skotzko M, Chandler C F, Morton D L, McBride W H, Economou J S. Interleukin-6 production by human melanoma cell lines.  Lymphokine Cytokine Res. 1992;  11 161-166
    PubMedGoogle Scholar
  • 7 Francis G M, Krohn E G, Woods K V, Buzaid A C, Grimm E A. Interleukin-6 production and secretion in human melanoma cell lines, regulation by interleukin-1.  Melanoma Res. 1996;  6 191-201
    PubMedGoogle Scholar
  • 8 Lu C, Kerbel R S. Interleukin-6 undergoes transition from paracrine growth inhibitor to autocrine stimulator during human melanoma progression.  J Cell Biol. 1993;  120 1281-1288
    CrossrefPubMedGoogle Scholar
  • 9 Mattei S, Colombo M P, Melani C, Silvani A, Parmiani G, Herlyn M. Expression of cytokine/growth factors and their receptors in human melanoma and melanocytes.  Int J Cancer. 1994;  56 853-857
    PubMedGoogle Scholar
  • 10 Colombo M P, Maccalli C, Mattei S, Melani C, Radrizzani M, Parmiani G. Expression of cytokine genes, including Il-6, in human malignant melanoma cell lines.  Melanoma Res. 1992;  2 181-189
    PubMedGoogle Scholar
  • 11 Castell J V, Gomez-Lechon M J, David M, Andus T, Geiger T, Trullenque R, Fabra R, Heinrich P C. Interleukin-6 is the major regulator of acute phase protein synthesis in adult human hepatocytes.  FEBS Lett. 1989;  242 237-239
    CrossrefPubMedGoogle Scholar
  • 12 Moshage H J, Roelofs H MJ, van Pelt J F, Hazenberg B PC, van Leeuwen M A, Limburg P C, Aarden L A, Yap S H. The effect of interleukin-1, interleukin-6 and its interrelationship on the synthesis of serum amyloid A and C-reactive protein in primary cultures of adult human hepatocytes.  Biochem Biophys Res Commun. 1988;  155 112-117
    CrossrefPubMedGoogle Scholar
  • 13 Heimdal K, Hannisdal E, Gunderson S. Metastatic malignant melanoma.  Eur J Cancer. 1989;  25 1219-1223
    PubMedGoogle Scholar
  • 14 Keilholz U, Scheibenbogen C, Sommer M, Pritsch M, Geuke A M. Prognostic factors for response and survival in patients with metastatic melanoma receiving immunotherapy.  Melanoma Res. 1996;  6 173-178
    PubMedGoogle Scholar
  • 15 Sirott M N, Bajorin D F, Wong G YN, Tao Y, Chapman P B. Prognostic factors in patients with metastatic malignant melanoma.  Cancer. 1993;  72 3091-3098
    PubMedGoogle Scholar
  • 16 Balch C M, Buzaid A C, Atkins M B, Cascinelli N, Coit D G, Fleming I D, Houghton A, Kirkwood J M, Mihm M F, Morton D L, Reintgen D, Ross M I, Sober A, Soong S J, Thompson J A, Thompson J F, Gerhenwald J E, McMasters K M. A new American joint committee on cancer staging system for cutaneous melanoma.  Cancer. 2000;  88 1484-1491
    CrossrefPubMedGoogle Scholar
  • 17 Miller R, Siegmund D. Maximally selected chi square statistics.  Biometrics. 1982;  38 1011-1016
    PubMedGoogle Scholar
  • 18 Efron B, Tibshirani R J. An Introduction to the Bootstrap. New York; Chapman & Hall 1993
    Google Scholar
  • 19 DeLong E R, DeLong D M, Clarke-Pearson D L. Comparing the areas under two or more correlated receiver operating characteristic curves, a nonparametric approach.  Biometrics. 1988;  44 837-845
    CrossrefPubMedGoogle Scholar
  • 20 Hellmich M. Receiver Operating Characteristic (ROC) Kurven und Flächen darunter. Anwendungen in der Psychiatrie. Dissertationsschrift. Med. Fakultät, Universität Münster 1996
    Google Scholar
  • 21 Coughlin S S, Trock B, Criqui M H, Pickle L, Browner D, Tefft M C. The logistic modelling of sensitivity, specificity and predictive value of a diagnostic test.  J Clin Epidemiol. 1992;  45 1-7
    CrossrefPubMedGoogle Scholar
  • 22 Smith P J, Thompson T J, Engelgau M, Herman W H. A generalized linear model for analysing receiver operating characteristic curves.  Statistics in Medicine. 1996;  15 323-333
    CrossrefPubMedGoogle Scholar
  • 23 Harrell F E. Predicting outcomes, applied survival analysis and logistic regression. University of Virginia 2001
    Google Scholar
  • 24 Breiman L, Friedman J H, Olshen R A, Stone C J. Classification and Regression Trees. Belmont, CA; Wadsworth Inc 1984
    Google Scholar
  • 25 Lausen B, Sauerbrei W, Schumacher M. Classification and regression trees (CART) used for the exploration of prognostic factors measured on different scales. In: Dirschedl P, Ostermann R (Eds) Computational Statistics. Heidelberg; Physica Verlag 1994: 483-496
    Google Scholar
  • 26 Harman A J. Wilks' tolerance limit sample size. In: Sachs L (Ed) Angewandte Statistik. Heidelberg; Springer Verlag 1997: 215-218
    Google Scholar
  • 27 Deichmann M, Benner A, Jäckel A, Bock M, Waldmann V, Näher H. Elevated interleukin-6 serum levels indicate progressive disease in metastasized malignant melanoma.  J Exp Clin Cancer Res. 2000;  19 301-307
    PubMedGoogle Scholar
  • 28 Deichmann M, Benner A, Bock M, Jäckel A, Waldmann V, Uhl K, Näher H. S100-beta, melanoma-inhibiting activity, and lactate dehydrogenase discriminate progressive from nonprogressive American Joint Committee on Cancer stage IV melanoma.  J Clin Oncol. 1999;  17 1891-1896
    PubMedGoogle Scholar
  • 29 Deichmann M, Benner A, Kuner N, Wacker J, Waldmann V, Näher H. Are responses to therapy of metastasized malignant melanoma reflected by decreasing serum values of S100β or melanoma inhibitory activity (MIA)?.  Melanoma Res. 2001;  11 291-296
    CrossrefPubMedGoogle Scholar
  • 30 Paglia D, Oran A, Lu C, Kerbel R S, Sauder D N, McKenzie R C. Expression of leukemia inhibitory factor and interleukin-11 by human melanoma cell lines, LIF, Il-6 and Il-11 are not coregulated.  J Interferon Cytokine Res. 1995;  15 455-460
    PubMedGoogle Scholar
  • 31 Klein B, Zhang X G, Jourdan B, Content B, Content J, Houssiau F, Aarden L, Piechaczyk M, Bataille R. Paracrine rather than autocrine regulation of myeloma-cell growth and differentiation by interleukin-6.  Blood. 1989;  73 517-526
    PubMedGoogle Scholar
  • 32 Deichmann M, Thome M, Bock M, Jäckel A, Waldmann V, Näher H. The human herpesvirus-type 8 DNA is not detected in primary malignant melanoma.  Br J Cancer. 1999;  80 67-69
    CrossrefPubMedGoogle Scholar
  • 33 Helmke B M, Deichmann M, Otto H F. Anorectal melanomas do not harbour the Kaposi's sarcoma associated human herpesvirus type 8 DNA.  J Med Virol. 2001;  64 47-50
    CrossrefPubMedGoogle Scholar
  • 34 Motro B, Itin A, Sachs L, Keshet E. Patterns of interleukin-6 gene expression in vivo suggests a role for this cytokine in angiogenesis.  Proc Natl Acad Sci USA. 1990;  87 3092-3096
    PubMedGoogle Scholar
  • 35 Okuno Y, Takahashi T, Suzuki A, Fukumoto M, Nakamura K, Fukui H, Koishihira Y, Ohsugi Y, Imura H. Acquisition of growth autonomy and tumorigenicity by an interleukin 6-dependent human myeloma cell line transfected with interleukin 6 cDNA.  Exp Hematol. 1992;  20 395-400
    PubMedGoogle Scholar
  • 36 Noma T, Mizuta T, Rosen A, Hirano T, Kishimoto T, Honjo T. Enhancement of the interleukin 2 receptor expression on T cells by multiple B-lymphotropic lymphokines.  Immunol Lett. 1987;  15 249-253
    CrossrefPubMedGoogle Scholar
  • 37 Aderka D, Le J, Velcek J. Il-6 inhibits lipopolysaccharide-induced tumour necrosis factor production in cultured human monocytes, U937 cells, and in mice.  J Immunol. 1989;  143 3517-3524
    PubMedGoogle Scholar
  • 38 Zhou D, Munster A, Winchurch R A. Pathologic concentrations of interleukin 6 inhibit T cell responses via induction of activation of TGF-β.  FASEB J. 1991;  5 2582-2585
    PubMedGoogle Scholar
  • 39 Pepys M B. The acute phase response and C-reactive protein. In: Weatherall DJ, Ledingham JGG, Warrell DA (Eds) Oxford textbook of medicine. Oxford; Oxford University Press 1995: 1527-1533
    Google Scholar
  • 40 Bosserhoff A K, Kaufmann M, Kaluza B, Bartke I, Zirngibl H, Hein R, Stolz W, Buettner R. Melanoma-inhibiting activity, a novel serum marker for progression of malignant melanoma.  Cancer Res. 1997;  57 3149-3153
    PubMedGoogle Scholar
  • 41 Guo H B, Stoffel-Wagner B, Bierwirth T, Mezger J, Klingmüller D. Clinical significance of serum S100 in metastatic malignant melanoma.  Eur J Cancer. 1995;  31 924-928
    CrossrefPubMedGoogle Scholar
  • 42 Hein R, Bosserhof A K, Stolz W, Kaufmann M, Kaluza B, Buettner R. MIA serum levels as a detection and monitoring system of malignant melanoma.  Arch Dermatol Res. 1997;  289 30
    PubMedGoogle Scholar
  • 43 Henze G, Dummer R, Joller-Jemelka H I, Böni R, Burg G. Serum S100, a marker for disease monitoring in metastatic melanoma.  Dermatology. 1997;  194 208-212
    PubMedGoogle Scholar
  • 44 Hauschild A, Michaelsen J, Brenner W, Rudolph P, Glaser R, Henze E, Christophers E. Prognostic significance of serum S100β detection compared with routine blood parameters in advanced metastatic melanoma patients.  Melanoma Res. 1999;  9 155-161
    PubMedGoogle Scholar
  • 45 Hauschild A, Engel G, Brenner W, Glaser R, Monig H, Henze E, Christophers E. S100β protein detection is a significant prognostic factor in metastatic melanoma.  Oncology. 1999;  56 338-344
    PubMedGoogle Scholar
  • 46 Jäckel A, Deichmann M, Waldmann V, Bock M, Näher H. S100β protein in serum, a tumor marker in malignant melanoma, current state of knowledge and clinical experience.  Hautarzt. 1998;  50 250-256
    PubMedGoogle Scholar
  • 47 Dietz U, Sandell L J. Cloning of a retinoid acid-sensitive mRNA expressed in cartilage and during chondrogenesis.  J Biol Chem. 1996;  271 3311-3316
    CrossrefPubMedGoogle Scholar
  • 48 Fagnart O C, Sindic C JM, Laterre C. Particle counting immunoassay of S100 protein in serum, possible relevance in tumors and ischemic disorders of the central nervous system.  Clin Chem. 1988;  34 1387-1391
    PubMedGoogle Scholar
  • 49 Müller-Ladner U, Bosserhoff A K, Dreher K, Hein R, Neidhart M, Gay S, Scholmerich J, Buettner R, Lang B. MIA (melanoma inhibitory activity), a potential serum marker for rheumatoid arthritis.  Rheumatology. 1999;  38 148-154
    CrossrefPubMedGoogle Scholar

Dr. med. habil. M. Deichmann

Universitäts-Hautklinik Heidelberg

Voßstraße 2 · 69115 Heidelberg ·

eMail: martin_deichmann@med.uni-heidelberg.de